Merck Serono/Takeda Matuzumab Development In Question After Phase II Study
This article was originally published in PharmAsia News
Executive Summary
Merck Serono is reconsidering development of its monoclonal antibody matuzumab for the treatment of metastatic colorectal cancer after a Phase II study failed to meet its efficacy endpoint, the company announced Aug. 29